DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for choroiditis — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleChoroiditis maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for choroiditis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nuclear receptor subfamily 3 group C member 1 (NR3C1) — NR3C1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7KW7 · 3.57 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
SOLITARY IDIOPATHIC CHOROIDITIS WITH CHOROIDAL NEOVASCULARIZATION
AbstractPURPOSE: To report a case of solitary idiopathic choroiditis associated with choroidal neovascularization. METHOD: Case report of a 36-year-old healthy man who was referred for floaters in the left eye of 3 weeks' duration. RESULTS: Fundus examination of the left eye revealed a yellow-white subretinal lesion superior to the fovea. It was associated with a small subretinal hemorrhage and a macular detachment, which extended into the fovea. No vitreous cells were detected. The right eye was normal. The visual acuity was 20/20 in the right eye and 20/50 in the left eye. Laboratory evaluation for inflammatory or infectious diseases was nonrevealing. Fluorescein angiography showed Type 2 or so-called classic choroidal neovascularization associated with retinochoroidal anastomoses. After two laser treatments with poor outcomes, the lesion was effectively treated with oral steroids. A reactivation occurred 1.5 years later, and it was also successfully treated with oral steroids. CONCLUSION: Solitary idiopathic choroiditis can rarely be associated with choroidal neovascularization. Oral steroid treatment seems to be the preferred form of therapy rather than some form of interventional modality.
Killer cases due to occult choroidal inflammation : how to prevent them
AbstractAbstract Purpose Inflammation of the choroid evolves mostly unnoticed when only clinical examination and/or only classical investigational methods are used. In some cases such occult inflammation, when it is finally noted has already caused irremediable damage. Methods Inflammatory cases are presented that showed minimal or no signs on clinical examination/investigational tests, where significant occult choroïdal inflammation was detected by ICGA and that responded to therapy initiated on the base of ICGA findings. In parallel, patients that were treated with delay or received no therapy and suffered irremediable damage will be presented. Results Primary inflammatory choriocapillaropathies PICCPs (MEWDS, APMPPE, multifocal choroiditis) known to be caused by inflammatory choriocapillaris non perfusion can only be meaningfully investigated for activity by ICGA as non‐perfused areas are not seen otherwise. If active disease (non‐perfusion) is suspected, PICCPs have to be evaluated and followed by ICGA and in case of persistence of non‐perfusion and worsening of function, therapy has to be introduced to avoid irremediable damage. For stromal choroiditis such as Vogt‐Koyanagi‐Harada (VKH) disease, persisting choroiditis after alleged clinical recovery needing continued therapy can only be shown by ICGA, so avoiding complications due to smouldering occult disease. Conclusion ICGA in the work‐up of posterior uveitis should be part of a routine investigation for those case where angiographic work‐up is deemed necessary.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
